|
Organochlorines
|
Estrogen receptor positive
|
Estrogen receptor negative
|
|---|
|
in quartiles (ng/mL)
|
Cases/control
|
Adjusted RR (95% CI)a
|
p trendb
|
Cases/controls
|
Adjusted RR (95% CI)
|
p trend
|
|---|
|
HCB
|
|
I
|
<206.50
|
13/15
|
1.0 ref.c
| |
7/4
|
1.0
| |
|
II
|
206.50-269.75
|
15/14
|
0.7 (0.3-1.6)
| |
8/3
|
0.9 (0.3-3.1)
| |
|
III
|
269.75-335.75
|
17/12
|
1.1 (0.5-2.4)
| |
3/8
|
0.2 (0.0-1.2)
| |
|
IV
|
>335.75
|
13/15
|
1.1 (0.5-2.5)
|
>0.20
|
4/7
|
0.2 (0.1-1.7)
|
0.03
|
|
Dieldrin
|
|
I
|
<12.01
|
8/21
|
1.0
| |
4/7
|
1.0
| |
|
II
|
12.01-28.30
|
17/12
|
3.4 (1.3-8.7)
| |
3/8
|
0.4 (0.1-3.1)
| |
|
III
|
28.30-57.11
|
17/12
|
2.6 (1.0-6.3)
| |
7/4
|
1.9 (0.5-7.8)
| |
|
IV
|
>57.11
|
17/12
|
2.2 (0.9-5.4)
|
>0.20
|
8/3
|
1.8 (0.3-5.5)
|
0.06
|
|
ΣPCB
|
|
I
|
<811.11
|
14/15
|
1.0
| |
6/5
|
1.0
| |
|
II
|
811.11-1076.04
|
15/14
|
1.5 (0.6-3.4)
| |
7/4
|
0.4 (0.1-1.6)
| |
|
III
|
1076.04-1405.73
|
13/16
|
1.0 (0.4-2.3)
| |
5/6
|
0.5 (0.1-2.2)
| |
|
IV
|
>1405.73
|
17/12
|
2.5 (1.1-5.7)
|
>0.20
|
4/7
|
0.1 (0.0-5.6)
|
0.02
|
|
p,p'-DDE
|
|
I
|
<741.04
|
15/14
|
1.0
| |
6/5
|
1.0
| |
|
II
|
741.04-1129.75
|
13/16
|
0.7 (0.3-1.6)
| |
4/7
|
0.3 (0.0-2.0)
| |
|
III
|
1129.75-1688.85
|
17/12
|
1.0 (0.5-2.2)
| |
5/6
|
0.7 (0.1-3.7)
| |
|
IV
|
>1688.85
|
14/15
|
1.0 (0.5-2.1)
|
>0.20
|
7/4
|
0.3 (0.1-2.1)
|
>0.20
|
-
a Relative risk of dying, 95% confidence interval, adjusted for age at diagnosis, metastatic lymph nodes, and tumor size; b two sided p-value for linear trend in RR's; c Reference category. Cases with missing information on confounders were excluded.
